HLA-DR-associated invariant chain (CD74) plays a role in antigen presentation.
| Inventor | Institute |
|---|---|
| Karen Pulford | University of Oxford |
| Cat. #: | 151372 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Immunology |
| Application: | FACS ; IHC ; IF ; IP ; WB |
| Target: | Human Leukocyte Antigen-DR locus (HLA-DR) associated invariant chain (CD74) |
| Reactivity: | Human |
| Clone: | By2 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | CD74 Molecule; HLA-DR Antigens-Associated Invariant Chain; Gamma Chain Of Class II Antigens; Ia-Associated Invariant Chain; MHC HLA-DR Gamma Chain; DHLAG; P33; CD74 Antigen; Ia-GAMMA; HLADG |
|---|---|
| Product description: | HLA-DR-associated invariant chain (CD74) plays a role in antigen presentation. In addition to its expression on antigen-presenting cells, CD74 is expressed by carcinomas of renal, lung, gastric, and thymic origin and by certain sarcomas. The restricted expression of CD74 by normal tissues and its very rapid internalization make CD74 an attractive therapeutic target for both cancer and immunologic diseases. It has also been shown to have value as a gastric carcinoma marker. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | B cell lymphoma cells |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | HLA-DR-associated invariant chain (CD74) plays a role in antigen presentation. In addition to its expression on antigen-presenting cells, CD74 is expressed by carcinomas of renal, lung, gastric, and thymic origin and by certain sarcomas. The restricted expression of CD74 by normal tissues and its very rapid internalization make CD74 an attractive therapeutic target for both cancer and immunologic diseases. It has also been shown to have value as a gastric carcinoma marker. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Jones M et al. 1995. Workshop mAb B029 (By2) – a new B-cell marker for use in diagnostic pathology. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 1, Oxford University Press, Oxford, New York and Tokyo, p 710-11. ISBN-13: 978-0198577980 Mason D. et al (eds) CD Guide for CD74 (2002) Leucocyte Typing VII, Oxford University Press, Oxford and New York, p 825-6. ISBN-13: 978-0192632524 |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.